Prospects for future studies in head and neck cancer

European Journal of Surgical Oncology

Volumn 23, Issue 6, 1997, Pages 486-491

  Van Dongen, Guus A M S ^a   Snow, Gordon B ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antibody based therapy; Gene therapy; Head and neck cancer; Photodynamic therapy

Indexed keywords

CANCER ANTIBODY;

ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; GENE THERAPY; HEAD AND NECK CANCER; HUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL;

EID: 0031471650     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0748-7983(97)92789-X     Document Type: Article

References (45)

1. Gluckman JL. Hematoporphyrin photodynamic therapy: is there truly a future in head and neck oncology? Reflections on a 5-year experience. Laryngoscope 1991; 101: 36-42.
2. Tong MCF, Van Hasselt CA, Woo JKS. Preliminary results of photodynamic therapy for recurrent nasopharyngeal carcinoma. Eur Arch Otorhinolaryngol 1996; 253: 189-92.
3. Dilkes MG, DeJode ML, Rowntree-Taylor A, McGilligan JA, Kenyon GS, McKelvie P. m-THPC photodynamic therapy for head and neck cancer. Lasers Med Sci 1996; 11: 23-9.
4. Savary J-F, Monnier P, Fontolliet C, Mizeret J, Wagnières G, Braichotte D, Van den Bergh H. Photodynamic therapy for early squamous cell carcinomas of the esophagus, bronchi, and mouth with m-Tetra(hydroxyphenyl)chlorin. Arch Otolaryngol Head Neck Surg 1997; 123: 162-8.
5. Wenig BL, Kurtzman DM, Grossweiner LI, et al. Photodynamic therapy in the treatment of squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1990; 116: 1267-70.
6. Feyh J, Gutmann R, Leunig A. Photodynamic therapy in head and neck surgery. Laryngo-Rhino-Otol 1993; 72: 273-8.
7. Grant WE, Hopper C, Speight PM, Macrobert AJ, Brown SG. Photodynamic therapy of malignant and premalignant lesions in patients with 'field cancerization' of the oral cavity. J Laryngol Otol 1993; 107: 1140-5.
8. Biel MA. Photodynamic therapy and the treatment of neoplastic diseases of the larynx. Laryngoscope 1994; 104: 399-403.
9. Clayman GL. Gene therapy for head and neck cancer. Head & 1995; 17: 535-41.
10. Wollenberg B, Naujoks K, Kastenbauer E. Somatic gene therapy in squamous epithelial carcinomas in the head and neck area. Larygo-Rhino-Otologie 1996; 75: 95-9.
11. Lalwani AK, Han JJ, Carvalho GJ, Mhatre AN. The promise of gene therapy in otolaryngology-head and neck surgery. Curr Opin Otolaryngol Head Neck Surg 1997; 5: 197-202.
12. Roth JA, Cristiano RJ. Gene therapy for cancer. What have we done and where are we going? J Natl Cancer Inst 1997; 88: 21-39.
13. Whiteside TL, Chikamatsu, Nagashima S, Okadu K. Antitumor effects of cytolytic T lymphocytes (CTL) and natural killer (NK) cells in head and neck cancer. Anticancer Res 1996; 16: 2357-64.
14. Wang MB, Lichtenstein A, Mickel RA. Hierarchical immunosuppression of regional lymph nodes in patients with head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg 1991; 105: 517-27.
15. O'Malley BW, Chen S-H, Schwartz MR, Woo SLC. Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in nude mouse model. Cancer Res 1995; 55: 1080-5.
16. Wilson KM, Stambrook PJ, Bi WL, Pavelic ZP, Pavelic L, Gluckman JL. HSV-tk gene therapy in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1996; 122: 746-9.
17. Clayman GL, El-Naggar AK, Roth JA, Zhang W-W, Goepfert H, Taylor DL, Liu T-J. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 1995; 55: 1-6.
18. Liu T-J, Zhang W-W, Taylor DL, Roth JA, Goepfert H, Clayman GL. Growth suppression of human head and neck cancer cells by the introduction of a wild type p53 gene via a recombinant adenovirus. Cancer Res 1994; 54: 3662-7.
19. Brennan JA, Mao L, Hruban RH, et al. Molecular assessment of histopathological staging in squamous cell carcinoma of the head and neck. N Engl J Med 1995; 332: 429-35.
20. Van Dongen GAMS, Brakenhoff RH, Ten Brink C, Van Gog FB, De Bree R, Quak JJ, Snow GB. Squamous cell carcinoma-associated antigens used in novel strategies for the detection and treatment of minimal residual head and neck cancer. Anticancer Res 1996; 16: 2409-14.
21. Riethmüller G, Schneider-Gädicke E, Schlimok G, et al. and the German Cancer Aid 17-1A Study Group. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes'C coloreclal carcinoma. Lancet 1994; 343: 1177-83.
22. Kaminski MS, Zasadny KR, Francis IR, et at. Iodine-131-anti-B1 radioimunotherapy for B-cell lymphoma. J Clin Oncol 1996; 14: 1974-81.
23. Wilder RB, DeNardo GL, DeNardo SJ. Radioimmunotherapy: recent results and future directions. J Clin Oncol 1996; 14: 1383-1400.
24. Grandis JR, Melhem MF, Barnes EL, Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996; 78: 1284-92.
25. Schnürch HG, Stegmüller M,Vering A, Beckmann MW, Bender HG. Growth inhibition of xenotransplanted human carcinoma by a monoclonal antibody directed against the epidermal growth factor receptor. Eur J Cancer 1994; 30A: 491-6.
26. Aboud-Pirak E, Hurwitz E, Pirak ME, Bellot F, Schlessinger J, Sela M. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst 1993; 80: 1605-11.
27. Divgi CR, Welt S, Kris M, et al. Phase 1 and imaging trial of indium-III-labelled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung cancer. J Natl Cancer Inst 1991; 83: 97-104.
28. Perez-Soler R, Donato NJ, Shin DM, et al. Tumor epidermal growth factor receptor studies in patients with non-small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852. J Clin Oncol 1994; 12: 730-9.
29. Bier H, Reiffen KA, Haas I, Stasiccki P. Dose-dependent access of murine anti-epidermal growth factor receptor monoclonal antibody to tumor cells in patients with advanced laryngeal and hypopharyngeal carcinoma. Eur Arch Otorhinol 1995; 252: 433-9.
30. Modtjahedi H, Hickish T, Nicolson M, et al. Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. Br J Cancer 1996; 73: 228-35.
31. Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller Jr WH, Mendelsohn J. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993; 85: 1327-33.
32. Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993; 53: 4637-42.
33. Brakenhoff RH, Gerretsen M, Knippels ECM, et al. The human E48 antigen, highly homologous to the murine Ly-6 antigen ThB, is a GPI-anchored molecule apparently involved in keratinocyle cell-cell adhesion. J Cell Biol 1995; 129: 1677-89.
34. Schrijvers AHGJ, Quak JJ, Uyterlinde AM, Van Walsum M, Meijer CJLM, Snow GB, Van Dongen GAMS. MAb U36, a novel monoclonal antibody successful in immunotargetting of squamous cell carcinoma of the head and neck. Cancer Res 1993; 53: 4383-90.
35. Van Hal NLW, Van Dongen GAMS, Rood-Knippels EMC, Van der Valk P, Snow GB, Brakenhoff RH. Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous cell carcinoma, recognizes a CD44 isoform. Int J Cancer 1996; 69: 520-7.
36. Heider K-H, Sproll M, Susani S, et al. Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas. Cancer Immunol Immunother 1996; 43: 245-53.
37. 2. J Nucl Med 1994; 35: 775-83.
38. 99mTc-labeled monoclonal antibody U36 and its biodistribution in patients with head and neck cancer. Clin Cancer Res 1995; 1: 591-8.
39. De Bree R, Roos JC, Plaizier MABD, Quak JJ, Van Kamp GJ, Den Hollander W, Snow GB, Van Dongen GAMS. Selection of monoclonal antibody E48 IgG or U36 IgG for adjuvant radioimmunotherapy in head and neck cancer patients. Brit J Cancer 1997; 75: 1049-60.
40. Wessels BW, Harisiadis L, Carabell SC. Dosimetry and radiobiological efficacy of clinical radioimmunotherapy. J Nucl Med 1989; 30: 827.
41. 186Re-labeling of monoclonal antibodies for clinical application: pitfalls and solutions. Cancer 1997; (in press).
42. 186Re-labeled monoclonal antibody E48 IgG mediated therapy of human head and neck squamous cell carcinoma xenografts. Cancer Res 1993; 53: 3524-9.
43. 186Re-labeled MAb E48 IgG. Cell Biophys 1994; 24: 135-42.
44. 131I-labeled monoclonal antibody E48. Br J Cancer 1992; 66: 496-502.
45. Maraveyas A, Myers M, Stafford N, Rowlinson-Busza G, Stewart JSW, Epenetos AA. Radiolabeled antibody combined with external radiotherapy for the treatment of head and neck cancer: reconstruction of a theoretical phantom of the larynx for radiation dose calculation to local tissues. Cancer Res 1995; 55: 1020-7.